Clinical trials: Hyperkalaemia
Hyperkalemia, Hypokalemia
Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
China National Heart Failure Registration Study (CN-HF) is a nationwide, hospital-based, multicentre, prospective registry study sponsored by Ministry of Science and Technology of the People's Republic of China.
- Conditions
- Hyperkalemia, Hypokalemia, Heart Failure
- Trial name
- SPLENDID (NCT05184998)
- Where
- China
- Volunteers
- 6,950 people
- Sponsor
- AstraZeneca
Hyperkalemia
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
The purpose of this study is to evaluate the change in serum potassium levels from start of treatment to Day 14, when patiromer is administered at different doses, once daily, in children 2 - < 18 years of age with chronic kidney…
- Trial name
- EMERALD (NCT03087058)
- Testing
- Patiromer
- Where
- 30 sites in United States, Bulgaria and 5 more
- Volunteers
- 23 people
- Sponsor
- Vifor Pharma, Inc.
Hyperkalemia
Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.
- Trial name
- EMERALD2 (NCT05766839)
- Testing
- Patiromer
- Where
- 37 sites in United States, Australia and 13 more
- Volunteers
- 36 people
- Sponsor
- Vifor Pharma, Inc.
Hyperkalemia Elevated Plasma K+ Cardiovascular Disease (CVD)
Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network (HEKATE)
This is a cross-sectional retrospective study of laboratory records of patients who take electrolytes blood tests containing the data of the serum potassium level.
- Trial name
- NCT03657875
- Where
- Russia
- Volunteers
- 53,940 people
- Sponsor
- AstraZeneca
Hyperkalaemia
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children.
- Trial name
- PEDZ-K (NCT03813407)
- Testing
- Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1), Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)
- Where
- 70 sites in United States, Brazil and 11 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Hyperkalemia
A Multicenter Study to Evaluate the Nutritional Suitability of Renastart
A multicenter, open label, uncontrolled study to evaluate the acceptability, tolerability, and nutritional suitability of a medical food (Renastart, Vitaflo International Ltd) specially formulated to meet the unique nutritional…
- Trial name
- Renastart (NCT02825784)
- Testing
- Renastart
- Where
- 3 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Vitaflo International, Ltd